Exploring Adebrelimab With Chemotherapy Before Surgery for Advanced Esophageal Squamous Cell Carcinoma

What this Trial Is About

Researchers are evaluating the safety and effectiveness of neoadjuvant adebrelimab combined with chemotherapy in patients diagnosed with locally advanced esophageal squamous cell carcinoma ESCC. This exploratory, single-arm Phase 2 clinical study aims to understand how well this combination works before surgery in this patient group. The study is being conducted by The Affiliated Hospital of Putian University and focuses on patients with confirmed ESCC at specific clinical stages who have not yet received prior anti-tumor treatments. Participants will receive adebrelimab at a dose of 1200 mg or 20 mgkg through intravenous infusion every three weeks. They will also receive chemotherapy consisting of nanoparticle albumin-bound paclitaxel Nab-paclitaxel 100 mgm on days 1 and 8, and cisplatin 75 mgm on days 1, 2, and 3, both administered every three weeks. This neoadjuvant treatment is given before planned surgical resection, and patients are predicted to be eligible for R0 resection, which aims for complete tumor removal. During the study, participants will be closely monitored through various assessments including pathological complete response rate four weeks after surgery, surgical resection success, disease-free survival, overall survival, and response rates up to three months. Safety will be tracked by recording adverse events for up to two years. The total participation time includes neoadjuvant treatment, surgery, and follow-up assessments extending to 24 months to evaluate long-term outcomes and safety.

Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study